Does intracoronary infusion of mesenchymal stem cells prevent heart failure in patients with acute myocardial infarction?
This expression of concern highlights significant data and ethical irregularities in a phase 3 trial of mesenchymal stem cells for post-MI heart failure.
The BMJ was alerted to post-publication discussion raising concerns about a variety of issues; some issues were apparent from the data that support the paper, and are linked to from the article.Examples of the issues identified include irregularities in the data, concern about the inclusion of participants who did not meet the age criteria specified in the study, and concerns about undeclared conflicts of interest and authorship.
A 2025 study studied this question.